Status:

NOT_YET_RECRUITING

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Immunoglobulin A Nephropathy (IgAN)

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Detailed Description

This is an open-label multicenter study where participants are randomized into one of two groups, where the only difference between the groups is the on-treatment biopsy time point, end of the first y...

Eligibility Criteria

Inclusion

  • Primary IgAN, confirmed by kidney biopsy, within 5 years prior to Screening
  • eGFR ≥45 mL/min/1.73 m2, based on the 2021 CKD-EPI equation, at Screening
  • Persistent proteinuria, defined as either
  • Total Urine Protein ≥0.5 g/day or UPCR ≥0.5 g/g in a 24-hour urine collection, at Screening, despite maximally tolerated dose or poorly tolerated supportive therapy or
  • IgAN diagnosis \<6 months prior to Screening with Total Urine Protein \>1.5 g/day or UPCR \>1.5 g/g in a 24-hour urine collection, at the time of clinical presentation or diagnosis
  • Body weight ≥45 kg and body mass index (BMI) ≤35.0 kg/m2, at Screening

Exclusion

  • Secondary forms of IgAN, as determined by the Investigator, in the setting of systemic disorders, infections, autoimmune disorders or neoplasias
  • Diagnosis of IgA vasculitis
  • Total IgG \<6.0 g/L at Screening
  • Any chronic urinary tract disorder, including but not limited to retention, incontinence, and/or recurrent urinary tract infections
  • Untreated hypertension or uncontrolled hypertension despite treatment (i.e., resistant hypertension)
  • Treatment with immunosuppressive or other immunomodulatory agents within 52 weeks prior to Screening
  • Other protocol-defined inclusion/exclusion criteria may apply.

Key Trial Info

Start Date :

November 18 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 16 2030

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT07146906

Start Date

November 18 2025

End Date

July 16 2030

Last Update

August 28 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.